Rationale for statins in the chemoprevention of prostate cancer.

Rationale for statins in the chemoprevention of prostate cancer.

Item
http://www.wikidata.org/entity/Q37258845
Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatasesAssociation of statin use with pathological tumor characteristics and prostate cancer recurrence after surgeryChemopreventive efficacy of Atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties.Statin use in relation to prostate cancer outcomes in a population-based patient cohort study.Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.Blood lipid levels and prostate cancer risk; a cohort studyUse of statins and prostate cancer recurrence among patients treated with radical prostatectomy
P2860

Rationale for statins in the chemoprevention of prostate cancer.

Item
http://www.wikidata.org/entity/Q37258845
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rationale for statins in the chemoprevention of prostate cancer.
@en
Rationale for statins in the chemoprevention of prostate cancer.
@nl
type
label
Rationale for statins in the chemoprevention of prostate cancer.
@en
Rationale for statins in the chemoprevention of prostate cancer.
@nl
prefLabel
Rationale for statins in the chemoprevention of prostate cancer.
@en
Rationale for statins in the chemoprevention of prostate cancer.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Rationale for statins in the chemoprevention of prostate cancer
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P698